Artivion

AORT

Market cap $2.15B

Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.

Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.

Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Artivion Third Quarter 2025 Earnings Call. [Operator Instructions].

Artivion (AORT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025 Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024 Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for Arcevo ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2025. "Our third quarter performance was exceptionally strong as we made progress across each of our strategic initiatives while delivering 16% constant currency revenue growth.

ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA") in the treatment of acute and chronic arch pathologies. The trial is designed to support the Company's forthcoming application to the U.S. Food and Drug Administration (FDA) for Premarket Approval (PMA) of Arcevo LSA.

ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at the Lotte New York Palace Hotel. The Company's fireside chat is scheduled to begin at 8:00 a.m.

ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data from the AMDS PROTECT Trial Validate Statistically Significant Positive Outcomes Demonstrated by the PERSEVERE and DARTS trials ATLANTA , Oct. 13, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS PERSEVERE and PROTECT trials were presented in Late-Breaking Science presentations at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Copenhagen, Denmark. The AMDS PERSEVERE trial presentation highlighted positive 30-day data focused on a subset of patients with visceral and renal malperfusion.

Artivion, Inc. (NYSE:AORT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants James Mackin - Chairman, President & CEO Lance Berry - COO, CFO & Treasurer Presentation Unknown Analyst Perfect. Great. Thanks, everyone, for being with us.